Pidnarulex is under clinical development by Senhwa Biosciences and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pidnarulex’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pidnarulex overview

Pidnarulex is under development for the treatment of relapsed/refractory haematological malignancies including non-Hodgkin lymphoma, acute myeloid leukemia, multiple myeloma, triple negative breast cancer, chemotherapy resistant epithelial ovarian cancer, pancreatic cancer, ovarian cancer, peritoneal cancer, fallopian tube cancer, prostate cancer, breast cancer, pediatric neuroblastoma and other cancers. It is administered through intravenous route. The drug candidate targets RNA polymerase I and topoisomerase II beta. It is a G4-stabilizing compound. The drug candidate is developed based on synthetic lethality technology. It was also under development for advanced castration-resistant prostate cancer.

Senhwa Biosciences overview

Senhwa Biosciences (Senhwa) is a clinical-stage drug development company. It develops next-generation deoxyribonucleic acid (DNA) damage response drugs for the treatment of cancer. Its pipeline products include CX-5461 and CX-4945. The company’s pidnarulex (CX-5461) product is used for the treatment of breast cancer, ovarian cancer or solid tumors and hematological malignancies. The company’s other product candidate silmitasertib CX-4945 is used for the treatment of prostate cancer, cholangiocarcinoma, basal cell carcinoma, medulloblastoma and COVID-19. It collaborates with global investigators and service providers to develop its pipeline products. The company has operations in Taiwan and the US. Senhwa is headquartered in New Taipei City, Taipei, Taiwan.

For a complete picture of Pidnarulex’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.